Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its participation in two virtual investor conferences in June 2021. The 2021 LD Micro Invitational XI will feature presentations by Scott Curtis and Dr. Joseph Stauffer on June 9 at 12:30 pm ET. The Raymond James Human Health Innovation Conference will showcase Dan Legault and Dr. Stauffer on June 23 at 8:40 am ET. Replays will be available for 90 days on the company's website. Antibe focuses on developing safer therapies for inflammation, including otenaproxesul, currently entering Phase III for osteoarthritis pain.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June:

2021 LD Micro Invitational XI, Live company presentation by Scott Curtis, Executive VP, and Dr. Joseph Stauffer, Chief Medical Officer, on Wednesday, June 9, 2021 at 12:30 pm (Eastern Time).

Raymond James Human Health Innovation Conference, Live company presentation by Dan Legault, CEO, and Dr. Joseph Stauffer on Wednesday, June 23, 2021 at 8:40 am (Eastern Time).

A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005219/en/

FAQ

When is Antibe Therapeutics participating in the LD Micro Invitational XI?

Antibe Therapeutics will participate in the LD Micro Invitational XI on June 9, 2021, at 12:30 pm ET.

Who will present at the Raymond James Human Health Innovation Conference?

Dan Legault and Dr. Joseph Stauffer will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:40 am ET.

How can I watch the presentations from Antibe Therapeutics?

The presentations from Antibe Therapeutics will be available via webcast on their website, with replays for 90 days.

What is the focus of Antibe Therapeutics' drug development?

Antibe Therapeutics focuses on developing safer therapies for inflammatory conditions, including their lead drug, otenaproxesul, for osteoarthritis pain.

What is the ticker symbol for Antibe Therapeutics?

The stock ticker symbol for Antibe Therapeutics is ATBPF.